ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment

ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.

Read more »

OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug

OXiGENE shares rose in pre-market trading Monday

Read more »

Emergent BioSolutions Acquires Rights To Lymphoma Drug

Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.

Read more »

YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment

YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.

Read more »

ReNeuron Treats Third Stroke Patient In Phase I Trials Of Stem Cell Therapy

ReNeuron said this morning the last of the stroke patients in the initial dosing group has been treated with the group’s new stem cell therapy.

Read more »

NeoStem To Drive Shareholder Value, Says Rodman & Renshaw

NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.

Read more »

Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure

Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.

Read more »

ImmunoCellular To Present Encouraging Phase 1 Study Results For Brain Tumour Treatment

ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.

Read more »

Access Pharmaceuticals Inks Deal To Expand MuGard Distribution

Access Pharmaceuticals announced Tuesday it has signed an agreement with eMax Health Systems to expand the distribution of the company’s MuGard treatment.

Read more »

Valeant Pharmaceuticals to acquire Lithuania’s Sanitas for $442m

Valeant Pharmaceuticals said Tuesday that it agreed to buy Lithuania-based generic drug company Sanitas for €314 million in cash.

Read more »